This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 May 2011

USFDA Approves Hepatitis C Drug Incivek

With the approval of Incivek, there are now two important new treatment options for hepatitis C.

The US FDA has approved a new hepatitis C drug Incivek (telaprevir) manufactured by Vertex Pharmaceuticals. Incivek becomes the second hepatitis C drug approved within two weeks, after almost a decade of no new treatments for the disease.


The drug will be made available to patients who have either not received interferon-based drug therapy for their infection or have not responded adequately to prior therapies.


Prior to the approvals, the standard of care for patients with chronic hepatitis C infection was peginterferon alfa and ribavirin for 48 weeks, but less than 50% of patients respond to this therapy.


A Phase III trial for Inci

Related News